Intellectual Property partners Michael W. Johnson and Heather M. Schneider, associate Tara L. Thieme, and Taylor Wessing Life Science partner Judith Krens participated in the latest Willkie Biosimilar Webinar Series, “Trade Secret Updates: Litigation Developments and IP Waivers.”
The webinar discussed how trade secret claims have come to the forefront of several key issues facing biologic and biosimilar developers. In the first part of this webinar, they explored how trade secret litigation has evolved to play an increasingly central role in biosimilars-related disputes both in the U.S. and Europe. In the second half, they focused on how trade secrets may be treated under the hotly-contested COVID-19 IP waivers, and how these policies may shape product development for years to come.
Watch the recorded webinar here.